Unbiased metabolome screen leads to personalized medicine strategy for amyotrophic lateral sclerosis.

ABSTRACT: Amyotrophic lateral sclerosis is a rapidly progressive neurodegenerative disease that affects 1/350 individuals in the United Kingdom. The cause of amyotrophic lateral sclerosis is unknown in the majority of cases. Two-sample Mendelian randomization enables causal inference between an exposure, such as the serum concentration of a specific metabolite, and disease risk. We obtained genome-wide association study summary statistics for serum concentrations of 566 metabolites which were population matched with a genome-wide association study of amyotrophic lateral sclerosis. For each metabolite, we performed Mendelian randomization using an inverse variance weighted estimate for significance testing. After stringent Bonferroni multiple testing correction, our unbiased screen revealed three met

SUBMITTER: Boddy S 

PROVIDER: S-EPMC9010771 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature